P21 (P021)

P21, also written P021, is a short synthetic peptide engineered by researchers at the New York State Institute for Basic Research in Developmental Disabilities, led by Khalid Iqbal, from a fragment of ciliary neurotrophic factor (CNTF), a naturally occurring cytokine that supports the survival and growth of neurons and glial cells. The peptide's core sequence, an acetylated, C-terminally amidated hexapeptide with the sequence Ac-DGGLAG-NH2, corresponds to a short region near residues 148 to 151 of human CNTF, to which the researchers attached an adamantylated glycine to improve stability and brain penetration. P21 is not approved for any human use, is not in registered human clinical trials as of this writing, and is sold through unregulated research-chemical vendors labeled for laboratory research use only. Its commercial development rights are held by Phanes Biotech, a company Iqbal co-founded and where he serves as chief scientific officer, a detail relevant to interpreting the origin and framing of the supportive literature described below.

Full-length CNTF signals through a receptor complex built around CNTFR-alpha, LIFR-beta, and gp130, activating the JAK-STAT3 pathway; this signaling supported motor neuron survival in preclinical models but produced anorexia, cramping, and injection-site reactions when full-length CNTF was tested clinically in amyotrophic lateral sclerosis, ending that development program. P21 is proposed to work differently: rather than agonizing this receptor complex directly, the developing laboratory's model holds that P21 competitively antagonizes leukemia inhibitory factor (LIF), a related cytokine that also signals through gp130-containing receptors, thereby reducing LIF-driven JAK-STAT3 activity. This shift is reported to increase CREB transcriptional activity and the transcription of brain-derived neurotrophic factor (BDNF). BDNF then engages its TrkB receptor and downstream PI3K-Akt signaling, producing inhibitory Ser9 phosphorylation of glycogen synthase kinase-3 beta (GSK3β) and, by extension, reduced hyperphosphorylation of the tau protein, a central driver of neurofibrillary tangle formation in Alzheimer disease. This entire signaling chain, from LIF antagonism through BDNF induction to GSK3β inhibition, has been described primarily in cell culture and in the 3xTg-AD mouse model by the originating laboratory, and each individual step would benefit from independent confirmation.

The strongest evidence for P21 comes from a multi-year dietary treatment program in the 3xTg-AD triple-transgenic mouse model of Alzheimer disease, which overexpresses mutant human amyloid precursor protein, presenilin-1, and tau. Starting P21 in the diet at 3 months of age, six to nine months before this model develops overt amyloid or tau pathology, and continuing to 18 to 21 months of age, rescued deficits in dendritic and synaptic proteins, restored markers of adult hippocampal neurogenesis, attenuated amyloid-beta and tau pathology on histology, improved performance on the Morris water maze and novel object location tasks, and was reported to markedly reduce mortality relative to vehicle-treated transgenic mice. A follow-up 2026 diffusion MRI study in the same model found partial normalization of white matter and gray matter microstructure with a similar dosing protocol. Nearly all of this evidence comes from one transgenic mouse strain and largely one research group; the clearest attempt at independent replication in a different disease model, a 2024 study of P21 in CDKL5 deficiency disorder, found a positive effect in cultured human cells but a largely negative effect on brain BDNF levels and neuroanatomy when the same peptide was given chronically to living mice. No human trial data of any kind exist for P21 in any indication.

P21's pharmacokinetic characterization is limited to mice, where the peptide showed a plasma half-life above 3 hours and substantial resistance to degradation in simulated gastric and intestinal fluid, properties attributed to the adamantylated glycine modification and used to justify oral, diet-mixed dosing in most published rodent studies; a separate study used intraperitoneal injection in adult mice for practical dosing reasons. No pharmacokinetic, safety, tolerability, or immunogenicity data exist for P21 in humans, and no regulatory agency has evaluated it for any indication. It is currently marketed to researchers and to the public through unregulated peptide vendors as a research chemical not intended for human consumption, a category that carries no guarantee of purity, potency, or accurate labeling, and its status as a preclinical drug candidate under a single company's development program should be weighed against the source and framing of the literature summarized on this page.

Mechanism of Action

From Full-Length CNTF to a Short Peptide Mimetic

Ciliary neurotrophic factor (CNTF) is a naturally occurring cytokine that supports the survival of motor neurons and other neuronal populations by signaling through a receptor complex built from CNTFR-alpha, LIFR-beta, and gp130, activating the JAK-STAT3 pathway. Full-length recombinant CNTF was tested clinically in amyotrophic lateral sclerosis on the strength of its neuroprotective effects in animal models, but the trials were stopped after the protein produced anorexia, severe cramping, and muscle pain in treated patients, effects thought to relate to CNTF’s broad activity at gp130-containing receptors outside the nervous system. P21, also called P021, was designed as an alternative: a short synthetic hexapeptide (Ac-DGGLAG-NH2) corresponding to a fragment near residues 148 to 151 of human CNTF, modified with an adamantylated glycine to improve stability and blood-brain barrier penetration. Because P21 is a small fragment rather than the intact CNTF protein, its developers propose that it acts through a narrower mechanism than full-length CNTF, though this narrower mechanism has been characterized almost entirely by the same laboratory that designed the peptide.

Proposed LIF Antagonism and BDNF Induction

The mechanistic model put forward by the originating laboratory holds that P21 does not agonize the CNTF receptor directly. Instead, P21 is proposed to act as a competitive antagonist of leukemia inhibitory factor (LIF), a related cytokine that signals through gp130-containing receptor complexes that overlap with the CNTF receptor system. By reducing LIF-driven activation of JAK kinases and STAT3, P21 is reported to increase the transcriptional activity of CREB, a transcription factor that binds the promoter of brain-derived neurotrophic factor (BDNF) and drives its expression. BDNF is one of the most extensively studied growth factors in neuroscience, with well-established roles in synaptic plasticity, dendritic growth, and memory formation through its receptor TrkB. This LIF-antagonism-to-BDNF-induction chain has been reported mainly in the 3xTg-AD mouse model and in cultured cells by the group that designed the peptide, and each step of the proposed pathway would benefit from confirmation by investigators outside that group.

GSK3β Inhibition and Tau Pathology

Downstream of proposed BDNF-TrkB signaling, P21 treatment is reported to activate the PI3K-Akt pathway, which produces inhibitory phosphorylation of glycogen synthase kinase-3 beta (GSK3β) at serine 9. GSK3β is one of the principal kinases responsible for phosphorylating the tau protein, and its overactivity is strongly associated with the hyperphosphorylated, aggregation-prone tau seen in Alzheimer disease and other tauopathies. In 3xTg-AD mice, a strain engineered to overexpress mutant human tau alongside amyloid precursor protein and presenilin-1, chronic P21 treatment has been reported to reduce tau hyperphosphorylation and slow the accumulation of amyloid-beta pathology, consistent with this GSK3β-centered mechanism. In cultured CDKL5-knockout human neuroblastoma cells, P21 similarly restored GSK3β signaling in vitro, providing a rare piece of evidence from outside the originating laboratory that is at least directionally consistent with the proposed mechanism, even though the same study found the effect did not translate into improved outcomes in living mice.

Dendritic, Synaptic, and Neurogenic Effects

The reported downstream consequences of this signaling cascade include increased expression of the dendritic marker MAP2, the synaptic markers PSD-95, synaptophysin, and the NMDA receptor subunit NR1, and the neurogenesis markers doublecortin and Ki-67 in the hippocampus and cortex of treated 3xTg-AD mice. These changes are proposed to reflect BDNF-driven support for dendritic arborization, synapse formation and maintenance, and the survival of newly generated neurons in the dentate gyrus. A 2026 diffusion MRI study extended this structural story to white matter, reporting that P21 treatment partially normalized fractional anisotropy in the corpus callosum and external capsule, changes the authors interpreted as consistent with improved oligodendrocyte maturation and myelination rather than only neuronal effects. All of these structural findings are measured in fixed or living rodent brain tissue using histological, biochemical, or MRI methods, and none has a direct human counterpart measurement reported for P21.

Clinical Evidence

The 3xTg-AD Alzheimer Mouse Program

The core evidence base for P21 comes from a multi-year research program using the 3xTg-AD triple-transgenic mouse model of Alzheimer disease, conducted by Khalid Iqbal’s group at the New York State Institute for Basic Research in Developmental Disabilities. Starting dietary P21 (60 nanomoles per gram of chow) at 3 months of age, six to nine months before this model develops overt amyloid or tau pathology, and continuing through 18 to 21 months of age, the program reported rescue of dendritic and synaptic protein deficits, restoration of adult hippocampal neurogenesis markers, attenuation of amyloid-beta and tau pathology, improved performance on the Morris water maze (escape latency and probe-trial time in the target quadrant, with differences reaching a p value below 0.001 in several comparisons) and novel object location task (discrimination index difference at p equal to 0.0072), and a marked reduction in mortality relative to vehicle-treated transgenic mice. A related 2026 diffusion MRI study using a similar dosing protocol reported partial normalization of white and gray matter microstructure. These are consistent, reproducible-within-the-same-lab findings across a decade of publications, but they come from one transgenic mouse model of a genetic, early-onset form of Alzheimer pathology, not from a model of the far more common sporadic, late-onset human disease, and from largely one laboratory.

Evidence Outside the Originating Laboratory: CDKL5 Deficiency Disorder

The clearest available test of whether P21’s proposed mechanism generalizes beyond its originating research program comes from a 2024 study of CDKL5 deficiency disorder, a rare genetic epileptic encephalopathy, conducted by an Italian research group with one shared co-author from the originating lab. In cultured CDKL5-knockout human neuroblastoma cells, P21 (1 and 10 micromolar) restored proliferation, survival, maturation, and GSK3β signaling, an in vitro finding directionally consistent with the Alzheimer mouse mechanism. However, when the same peptide was given chronically to living Cdkl5 knockout mice, orally in juveniles and by intraperitoneal injection in adults, it failed to raise brain BDNF levels or improve neuroanatomical deficits, and produced only limited behavioral improvement, mainly in cataleptic behavior. This split result, a positive cell-culture finding paired with a largely negative animal finding, is an important reason to treat the more impressive 3xTg-AD mouse findings as evidence specific to that model rather than as a general demonstration that P21 reliably produces neurotrophic benefit.

State of the Evidence

No human trial of P21 has been registered or published as of this writing. Every efficacy claim summarized on this page is a rodent behavioral, histological, biochemical, or imaging finding, or, in one case, an in vitro finding in a human cell line; none is a human clinical outcome. The evidence base is also unusually concentrated: the great majority of the positive published literature comes from one laboratory, whose principal investigator, Khalid Iqbal, co-founded and serves as chief scientific officer of Phanes Biotech, the company that holds the license to develop P21 as a drug. This is not evidence that the reported findings are inaccurate, but it is a material fact for weighing the literature, in the same way that heavy sponsor involvement in a drug’s pivotal trials is a material fact even when the trials themselves are well conducted. Readers should treat P21 as an early-stage, largely single-group, animal-only research program with one independent partial replication (positive in vitro, largely negative in vivo) rather than as an established or broadly validated neurotrophic intervention.

Safety and Tolerability

No systematic human safety or tolerability data exist for P21, because no human trial has been conducted. The rodent literature describes the peptide as well tolerated over multi-month dietary administration, but a formal, quantified toxicology dataset has not been published for independent review. By analogy, full-length CNTF, which shares part of P21’s proposed receptor pathway, produced anorexia, cramping, and muscle pain when tested clinically in amyotrophic lateral sclerosis; whether this analogy applies to P21, a much smaller peptide with a distinct proposed mechanism, is untested. The developing laboratory has noted antibody formation against the peptide as a theoretical possibility, though no immune reaction to P21 has been reported in the published work to date. Product obtained from unregulated research-chemical vendors carries additional, unquantified risk from unverified purity and labeling.

Regulatory Status

P21 (P021) is not approved by the FDA, the EMA, or any other regulatory authority for any human use, and no completed or ongoing registered human clinical trial exists for it as of this writing. It is at the preclinical stage of drug development, with commercial rights held by Phanes Biotech under license from the originating academic laboratory. Outside of that formal development program, P21 is sold by peptide vendors labeled explicitly for laboratory research use only and not for human consumption, a category that carries no pharmaceutical quality control, no independent verification of peptide content or purity, and no legal sanction for human use. P21 is not a controlled substance and does not appear on typical anti-doping prohibited lists, but its unapproved and unregulated status means any human use occurs entirely outside clinical or regulatory oversight.

Dosing Guidance

No human dose has been established for P21, and the figures below describe doses used in published rodent research only, not a recommended protocol. The 3xTg-AD Alzheimer mouse studies used P21 mixed into chow at 60 nanomoles per gram of feed, delivered continuously from 3 months of age (an early, pre-pathology stage in this model) through 18 to 21 months of age, equating to roughly 150 to 162 nanomoles per mouse per day based on typical food intake. A CDKL5 deficiency disorder study used the same dietary concentration orally in juvenile mice but switched to 750 nanomoles per mouse per day by intraperitoneal injection in adult mice, without a published comparison of the two routes in the same animals. In vitro work in cultured cells has used P21 at 1 to 10 micromolar. None of these figures scale directly to a human dose, and no titration, loading, or maintenance schedule has been validated in any species beyond mice.